Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Nordic Nanovector ASA ( (DE:8NN) ) has shared an announcement.
Thor Medical ASA is set to present its financial results for the first half of 2025 on August 29, inviting investors, analysts, and media to review its achievements and future vision. The interim financial report and presentation materials will be available online, with a live webcast option for remote attendees, reflecting the company’s commitment to transparency and stakeholder engagement.
More about Nordic Nanovector ASA
Thor Medical is an emerging supplier in the radiopharmaceutical industry, focusing on the production of radionuclides, particularly alpha particle emitters, from naturally occurring thorium. The company utilizes a proprietary production process that eliminates the need for irradiation or nuclear reactors, offering a reliable, environmentally friendly, and cost-efficient supply. Thor Medical is based in Oslo, Norway, and is publicly traded on the Oslo Stock Exchange under the ticker ‘TRMED’.
Average Trading Volume: 2,185,150
Current Market Cap: NOK956.6M
Find detailed analytics on 8NN stock on TipRanks’ Stock Analysis page.